Utilizing a neutralizing antibody against IL-2318,19, we demonstrate that preventative inhibition of IL-23 not only protects against the development of glucose intolerance and insulin insensitivity, but could also dampen the development of NAFLD. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.